AC Immune SA announced positive safety and immunogenicity results through week-100 for Part 1 of its VacSYn Phase 2 trial evaluating ACI-7104 in early-stage Parkinson’s disease. The study met all primary endpoints, demonstrating that the treatment was generally safe and well-tolerated across all 34 randomized patients. Immunogenicity results showed a 100% response rate after three immunizations, with robust antibody penetration into the cerebrospinal fluid and signals for target engagement. The company plans to submit the final design for Part 2 to the FDA and expects regulatory meetings in early 2027. AC Immune SA is a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases.
